糖尿病合并肺炎诊治路径中国专家共识
糖尿病患者因宿主免疫受损易合并肺炎,我国糖尿病合并肺炎高发、机会性感染病原体致病增多但检出率低、重症肺炎多见且病死率高,导致严重医疗和经济负担。国内呼吸与危重症医学科、内分泌科、微生物科和临床药学等专家结合国内外文献与我国临床实践,就糖尿病合并肺炎诊治路径制定本共识。
要点
- 糖尿病患者免疫受损,肺炎发生风险高且病情重。
- 我国糖尿病合并肺炎机会性感染病原体增多但检出率低。
- 多学科专家共识旨在规范糖尿病合并肺炎诊治路径。
核心结论
- 亟须多学科专家制定规范的糖尿病合并肺炎诊治路径以改善预后。
研究设计与样本
- 由呼吸与危重症医学科、内分泌科、微生物科和临床药学等专家基于国内外文献与临床实践制定共识。
主要发现
- 糖尿病患者因宿主免疫受损易合并各种感染,其中肺炎尤为多见。
- 我国糖尿病合并肺炎高发,机会性感染病原体致病增多但检出率低,重症肺炎多见且病死率高,导致严重医疗和经济负担。
临床怎么用
- 临床可参照本共识对糖尿病合并肺炎患者进行规范诊治。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with diabetes mellitus are prone to various infections owing to host immune impairment, especially pneumonia. In China, morbidity of pneumonia in patients with diabetes mellitus is high. And in case of pneumonia, patients with diabetes mellitus were of increased probability of opportunistic infections, low detection rate of pathogens, more severe pneumonia and high mortality, resulting in heavy medical and economic burdens. Therefore, it is urgent for multi-disciplinary experts to explore and formulate standards for diagnosis and treatment of pneumonia in patients with diabetes mellitus to improve the prognosis. Based on domestic and international literatures and clinical experiences of experts in respiratory and critical care medicine, endocrinology, microbiology and clinical pharmacy, a consensus was developed on the diagnosis and treatment of pneumonia in patients with diabetes mellitus. 糖尿病患者因宿主免疫受损易合并各种感染,其中肺炎尤为多见。我国糖尿病合并肺炎高发、机会性感染病原体致病增多但检出率低、重症肺炎多见且病死率高,导致严重的医疗和经济负担,因此亟须多学科专家共同探讨、制定规范的诊治路径,改善疾病预后。结合国内外文献和我国临床实践,国内呼吸与危重症医学科、内分泌科、微生物科和临床药学等专家就糖尿病合并肺炎诊治路径制定本共识。.
引用
- [Diagnosis and treatment pathway for pneumonia in patients with diabetes mellitus: a Chinese experts' consensus]. Zhonghua Jie He He Hu Xi Za Zhi. 2020. PMID: 32727174. doi:10.3760/cma.j.cn112147-20200114-00021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。